BioXcel Therapeutics is trading 6.12% down at $0.17 after it and its subsidiaries filed for Chapter 11 protection on August 27, 2026.
- The proposed court-supervised sale of substantially all assets to Teva Pharmaceuticals, the stalking-horse bidder, includes $57.5 million upfront plus potential milestone payments.
- The bankruptcy filing reported estimated liabilities of $100 million to $500 million and assets of $10 million to $50 million.
- Shares closed August 28, 2026, at $0.18, down 74.76%; the after-hours decline continues the bankruptcy-driven selloff.